Short fatty acid tail polymyxin derivatives and uses thereof
The present invention relates to a polymyxin derivative wherein the derivative has a total of three positive charges at physiological pH and wherein the terminal moiety (D) of the derivative comprises a total of 1 to 5 carbon atoms; and to a combination product comprising at least two such derivatives. The invention further relates to a method for sensitizing Gram-negative bacteria to an antibacterial agent by administering, simultaneously or sequentially in any order a therapeutically effective amount of said antibacterial agent and a derivative according to the present invention to said subject; to methods for developing novel antibiotics; and for sensitizing clinically important bacteria to a host defense mechanism complement present in serum. The invention also relates to a method of treating a subject for a gram-negative bacterial infection by administering a polymyxin derivative of the invention in combination with a second antibacterial agent. Finally, the invention relates to a process for preparing such polymyxin derivatives.
1. A polymyxin derivative or a pharmaceutically acceptable salt thereof comprising acetyl-Ts-cy[XXfLXXT] wherein X is Dab.
2. A pharmaceutical composition comprising at least one polymyxin derivative according to claim 1 , and at least one pharmaceutically acceptable carrier or excipient.
3. The pharmaceutical composition according to claim 2 , further comprising an antibacterial agent.
4. A method for sensitizing Gram-negative bacteria to an antibacterial agent, comprising administering, simultaneously or sequentially in any order, a therapeutically effective amount of said antibacterial agent and a polymyxin derivative according to claim 1 to a subject in need thereof.
5. The method of claim 4 , wherein said antibacterial agent is an agent against which the outer membrane of Gram-negative bacteria acts as a permeability barrier.
6. The method according to claim 5 , wherein said antibacterial agent is selected from the group consisting of: macrolides clarithromycin, azithromycin, and erythromycin; ketolides; clindamycin, a linkosamine; streptogramins; rifamycins rifampin, rifabutin, and rifalazile; fusidic acid; mupirocin; oxazolidinones; glycopeptide antibiotics vancomycin, dalbavancin, telavancin and oritavancin; fluoroquinolones; and bacitracin.
7. The method according to claim 4 , wherein said bacterium is selected from the group consisting of: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii and Acinetobacter baumannii.
8. A method for sensitizing Gram-negative bacteria to a host defense mechanism complement present in serum, comprising administering a polymyxin derivative according to claim 1 to a subject in need thereof during a clinical infection.
9. The method according to claim 8 , wherein said bacteria are selected from the group consisting of: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii and Acinetobacter baumannii.
10. A method for treating an infection in a subject caused by a Gram-negative bacterium, comprising administering a therapeutically effective amount of a polymyxin derivative according to claim 1 in combination with a second antibacterial agent to a subject in need thereof.
11. The method according to claim 10 , wherein said antibacterial agent is selected from the group consisting of: macrolides clarithromycin, azithromycin, and erythromycin; ketolides; clindamycin, a linkosamine; streptogramins; rifamycins rifampin, rifabutin, and rifalazile; fusidic acid; mupirocin; oxazolidinones; glycopeptide antibiotics vancomycin, dalbavancin, telavancin and oritavancin; fluoroquinolones; and bacitracin.
12. The method according to claim 10 , wherein said bacterium is selected from the group consisting of: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii and Acinetobacter baumannii.
13. A polymyxin derivative or a pharmaceutically acceptable salt thereof comprising acetyl-Tn-cy[XXfLXXT], wherein X is Dab.
14. A pharmaceutical composition comprising at least one polymyxin derivative according to claim 13 , and at least one pharmaceutically acceptable carrier or excipient.
15. The pharmaceutical composition according to claim 14 , further comprising an antibacterial agent.
16. A method for sensitizing Gram-negative bacteria to an antibacterial agent, comprising administering, simultaneously or sequentially in any order, a therapeutically effective amount of said antibacterial agent and a polymyxin derivative according to claim 13 to a subject in need thereof.
17. The method of claim 16 , wherein said antibacterial agent is an agent against which the outer membrane of Gram-negative bacteria acts as a permeability barrier.
18. The method according to claim 17 , wherein said antibacterial agent is selected from the group consisting of: macrolides clarithromycin, azithromycin, and erythromycin; ketolides; clindamycin, a linkosamine; streptogramins; rifamycins rifampin, rifabutin, and rifalazile; fusidic acid; mupirocin; oxazolidinones; glycopeptide antibiotics vancomycin, dalbavancin, telavancin and oritavancin; fluoroquinolones; and bacitracin.
19. The method according to claim 16 , wherein said bacterium is selected from the group consisting of: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii and Acinetobacter baumannii.
20. A method for sensitizing Gram-negative bacteria to a host defense mechanism complement present in serum, comprising administering a polymyxin derivative according to claim 13 to a subject in need thereof during a clinical infection.
21. The method according to claim 20 , wherein said bacteria are selected from the group consisting of: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii and Acinetobacter baumannii.
22. A method for treating an infection in a subject caused by a Gram-negative bacterium, comprising administering a therapeutically effective amount of a polymyxin derivative according to claim 13 in combination with a second antibacterial agent to a subject in need thereof.
23. The method according to claim 22 , wherein said antibacterial agent is selected from the group consisting of: macrolides clarithromycin, azithromycin, and erythromycin; ketolides; clindamycin, a linkosamine; streptogramins; rifamycins rifampin, rifabutin, and rifalazile; fusidic acid; mupirocin; oxazolidinones; glycopeptide antibiotics vancomycin, dalbavancin, telavancin and oritavancin; fluoroquinolones; and bacitracin.
24. The method according to claim 22 , wherein said bacterium is selected from the group consisting of: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii and Acinetobacter baumannii.